CN114010771A - Composition with articular cartilage repairing function and preparation and application thereof - Google Patents
Composition with articular cartilage repairing function and preparation and application thereof Download PDFInfo
- Publication number
- CN114010771A CN114010771A CN202111521287.9A CN202111521287A CN114010771A CN 114010771 A CN114010771 A CN 114010771A CN 202111521287 A CN202111521287 A CN 202111521287A CN 114010771 A CN114010771 A CN 114010771A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- articular cartilage
- weight
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001188 articular cartilage Anatomy 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 58
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 30
- 239000005018 casein Substances 0.000 claims abstract description 30
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000021240 caseins Nutrition 0.000 claims abstract description 30
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 29
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 28
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical class N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims abstract description 28
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 28
- 239000011712 vitamin K Substances 0.000 claims abstract description 28
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 28
- 229940046010 vitamin k Drugs 0.000 claims abstract description 28
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 19
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000003826 tablet Substances 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims description 15
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical group NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- FGAMKHCTXLHFAL-FRWAFGSFSA-L dipotassium (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O FGAMKHCTXLHFAL-FRWAFGSFSA-L 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- -1 ossein Chemical compound 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 9
- 230000037182 bone density Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 42
- 208000002193 Pain Diseases 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 19
- 210000000629 knee joint Anatomy 0.000 description 14
- 210000000845 cartilage Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 6
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 5
- 229960002442 glucosamine Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000968 fibrocartilage Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical group C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a composition with a function of repairing articular cartilage, and a preparation and application thereof. The composition with the function of repairing articular cartilage comprises, by weight, 100-300 parts of calcium carbonate, 100-200 parts of collagen, 200-400 parts of D-glucosamine salt, 100-300 parts of vitamin K and/or chondroitin sulfate and 10-50 parts of casein phosphopeptide. The preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the composition with the function of repairing the articular cartilage and preparing the mixture into tablets, powder, granules, capsules or pills. The composition with the function of repairing the articular cartilage is applied to the preparation of medicines, foods and health-care foods for repairing the joint degenerative disease. The invention enriches the market of health-care food for increasing bone density and can better serve the consumers. Bringing economic benefits for enterprises and countries.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition with a function of repairing articular cartilage, a preparation and an application thereof.
Background
Articular cartilage (articular cartilage) is the surface of the connective bone in the joint, covered with a layer of articular cartilage, either hyaline cartilage or fibrocartilage. The articular cartilage faces the joint cavity are even smooth, facilitating the movement between bones. Cartilage itself is elastic and therefore cushions the connected bones from shocks and impacts during walking, jumping and other movements. In addition, the elasticity of cartilage and its deformability also have a slight effect on increasing joint mobility. Articular cartilage is neither nervous nor vascular, and its nutrients are supplied primarily by synovial fluid and arterial branches surrounding the synovial lining of the joint capsule. Among these collagen fibers, chondrocytes, which gradually consist of flat-like to oval or round cells from the superficial layer to the deep layer, are scattered and distributed, and maintain the normal metabolism of articular cartilage. Joint degenerative disease, also known as hyperosteogeny, i.e., degenerative change of bone, is a manifestation of arthritis. The pathogenic factors of the disease are mainly caused by cartilage abrasion caused by unbalanced mechanical stress distribution or excessive load. Due to the continuous development of social profession, the cervical degenerative disease, the lumbar degenerative disease and the knee degenerative disease caused by cartilage abrasion are more and more, and products on the market for the joint degenerative disease are extremely lack, so that the development of a product capable of solving the problems is very necessary.
Disclosure of Invention
The first purpose of the invention is to provide a composition with the function of repairing articular cartilage; the second purpose is to provide the preparation of the composition with the function of repairing the articular cartilage; the third purpose is to provide the application of the composition with the function of repairing the articular cartilage.
The first purpose of the invention is realized by that the composition with the function of repairing articular cartilage comprises 100-300 parts of calcium carbonate, 100-200 parts of ossein, 200-400 parts of D-glucosamine salt, 100-300 parts of vitamin K and/or chondroitin sulfate and 10-50 parts of casein phosphopeptide by weight.
The second purpose of the invention is realized by adding pharmaceutically acceptable auxiliary materials into the composition with the function of repairing the articular cartilage to prepare tablets, powder, granules, capsules or pills.
The third purpose of the invention is realized by the application of the composition with the function of repairing the articular cartilage in the preparation of medicines, foods and health-care foods for repairing joint degenerative diseases.
The ossein (including ossein peptide) is one of the collagens existing in human bodies and animal bodies, is the main component of human articular cartilage, epiphyseal cartilage and trabecula, and 70-86% of bone organic matters are ossein. Arthralgia, swelling, stiffness, non-strength, rattling and cartilage abrasion are closely related to the loss of ossein and are not caused by calcium deficiency.
Glucosamine can promote cartilage regeneration, repair damaged articular cartilage, make the cartilage surface smooth, thick and elastic, and restore normal physiological and motion functions of the joint; glucosamine can synthesize and supplement joint synovial fluid, lubricate the surfaces of articular cartilage, and reduce friction and vibration between bone joints, thereby slowing cartilage degradation; the casein phosphopeptide improves the absorption and utilization of calcium, reduces the effect of osteoclast absorption and inhibits the bone resorption.
Chondroitin sulfate is a mucopolysaccharide substance, improves osteoarthritis, relieves joint pain, slows down joint impact force and protects cartilage.
Vitamin K is involved in skeletal metabolism. Promoting osteoblast formation, inhibiting osteoclast formation, and preventing osteoporosis and bone fracture. Vitamin K has irreplaceable inhibiting and repairing effects on arteriosclerosis, osteoarthropathy, hypertension and Parkinson's disease, and is a healthy associate of bones and blood vessels.
The invention adds ossein which can supplement the whole bone nutrition by the synergistic effect of glucosamine, calcium carbonate, chondroitin sulfate/vitamin K and casein phosphopeptide to really recover the worn cartilage. Calcium supplementation is one of the basic means for increasing bone density. The calcium carbonate used in the product is a legal calcium source, has high calcium content, is easy to absorb, has stable chemical properties, and is suitable for being added into food. The bone collagen is an important component (more than 70 percent) of the articular cartilage, and the glucosamine containing the bone collagen can really repair the cartilage; in addition, the collagen plays a role of a network adhesion structure in bones, inorganic substances (and salts) such as calcium, phosphorus, iron and the like are connected to form bones, the strength and the elasticity of the bones are increased, and the loss of calcium from the bones is inhibited. The D-glucosamine hydrochloride can promote synthesis of mucopolysaccharide, increase viscosity of joint bone fluid, improve metabolism of joint cartilage, promote proliferation of osteoblast, and inhibit bone turnover. Chondroitin sulfate is a mucopolysaccharide substance, improves osteoarthritis, relieves joint pain, slows down joint impact force and protects cartilage. The composition can be used in combination with glucosamine to relieve pain and promote cartilage regeneration, and can fundamentally improve joint problems. The casein phosphopeptide improves the absorption and utilization of calcium, reduces the effect of osteoclast absorption and inhibits the bone resorption. The invention determines the types of the raw materials through a large amount of literature research on the components and the effect of the raw materials, determines the dosage of the raw materials according to the health food registration management method and the Chinese resident dietary nutrient reference intake, further determines the product dosage form and the appropriate auxiliary materials according to the properties of the selected raw materials and the characteristics of the appropriate groups to form a primarily selected formula, and finally determines the product formula through a forming experiment.
The invention is an ammonia sugar formula containing ossein, which is added with the ossein, and has five effects of synergy with ammonia sugar, calcium carbonate, chondroitin sulfate/vitamin K and casein phosphopeptide, thereby balancing nutrition and repairing comprehensively. Particularly has obvious effect of repairing and relieving pain of articular cartilage and has obvious effect of healthy repair of joint degenerative diseases of middle-aged and elderly people. Enriches the market of health-care food for increasing the bone mineral density and can better serve the consumers. Bringing economic benefits for enterprises and countries.
Detailed Description
The present invention is further illustrated by the following examples, which are not intended to be limiting in any way, and any modifications or alterations based on the teachings of the present invention are intended to fall within the scope of the present invention.
The composition with the function of repairing articular cartilage comprises, by weight, 100-300 parts of calcium carbonate, 100-200 parts of collagen, 200-400 parts of D-glucosamine salt, 100-300 parts of vitamin K and/or chondroitin sulfate and 10-50 parts of casein phosphopeptide.
The composition with the function of repairing articular cartilage comprises, by weight, 150-265 parts of calcium carbonate, 100-140 parts of collagen, 200-400 parts of D-glucosamine salt, 150-200 parts of vitamin K and/or chondroitin sulfate and 10-30 parts of casein phosphopeptide.
The composition with the function of repairing the articular cartilage comprises, by weight, 200 parts of calcium carbonate, 150 parts of ossein, 300 parts of D-glucosamine salt, 200 parts of vitamin K and/or chondroitin sulfate and 20 parts of casein phosphopeptide.
The composition with the function of repairing articular cartilage comprises, by weight, 100-300 parts of calcium carbonate, 100-200 parts of ossein, 200-400 parts of D-glucosamine salt, 100-300 parts of vitamin K and 10-50 parts of casein phosphopeptide.
The composition with the function of repairing articular cartilage comprises, by weight, 150-265 parts of calcium carbonate, 100-140 parts of ossein, 200-400 parts of D-glucosamine salt, 150-200 parts of vitamin K and 10-30 parts of casein phosphopeptide.
The composition with the function of repairing articular cartilage comprises, by weight, 200 parts of calcium carbonate, 150 parts of ossein, 300 parts of D-glucosamine salt, 200 parts of vitamin K and 20 parts of casein phosphopeptide.
The vitamin K is vitamin K1 and vitamin K2.
The D-glucosamine salt is D-glucosamine hydrochloride or D-glucosamine potassium sulfate.
The preparation of the composition with the function of repairing the articular cartilage is prepared by adding pharmaceutically acceptable auxiliary materials into the composition with the function of repairing the articular cartilage and preparing the mixture into tablets, powder, granules, capsules or pills.
The tablet of the composition with the function of repairing the articular cartilage comprises the composition with the function of repairing the articular cartilage and auxiliary materials, wherein the auxiliary materials comprise 180-250 parts by weight of starch, 0-15 parts by weight of povidone K3010 and 3-10 parts by weight of magnesium stearate, and the preparation method comprises the steps of pretreatment, granulation, drying and tabletting, and specifically comprises the following steps:
A. pretreatment:
1) uniformly mixing calcium carbonate, ossein, casein phosphopeptide, vitamin K and/or chondroitin sulfate and starch in a formula ratio, adding D-glucosamine salt, and uniformly mixing to obtain a material a;
2) dissolving povidone K30 in the formula ratio by using an ethanol solution with the volume percentage concentration of 30-80% to prepare a povidone K30 ethanol solution with the mass percentage concentration of 2-10% to obtain a material b;
B. preparing a soft material: mixing the material a and the material b, and granulating to obtain wet granules c;
C. and (3) drying: drying the wet particles c at the temperature of 50-70 ℃ to obtain dry particles d;
D. tabletting: tabletting the dry granules d to obtain a composition tablet with the target object having the function of repairing articular cartilage; coating to obtain the composition coated tablet with the function of repairing articular cartilage.
The application of the composition with the function of repairing the articular cartilage is the application of the composition with the function of repairing the articular cartilage in preparing medicines, foods and health-care foods for repairing joint degenerative diseases.
The invention is further illustrated by the following specific examples:
example 1
Weighing 100g of calcium carbonate, 100g of ossein, 200g of D-glucosamine salt, 100g of chondroitin sulfate and 10g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 2
300g of calcium carbonate, 200g of ossein, 400g of D-glucosamine salt, 100g of vitamin K, 200g of chondroitin sulfate and 50g of casein phosphopeptide are weighed and mixed evenly to obtain the target composition with the function of repairing articular cartilage.
Example 3
Weighing 200g of calcium carbonate, 150g of ossein, 300g of D-glucosamine salt, 50g of vitamin K, 150g of chondroitin sulfate and 30g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 4
Weighing 210g of calcium carbonate, 180g of ossein, 350g of D-glucosamine salt, 270g of chondroitin sulfate and 40g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 5
Weighing 165g of calcium carbonate, 108g of ossein, 312g of D-glucosamine salt, 230g of chondroitin sulfate and 38g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 6
Weighing 100g of calcium carbonate, 100g of ossein, 200g of D-glucosamine salt, 100g of vitamin K and 10g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 7
Weighing 300g of calcium carbonate, 200g of ossein, 400g of D-glucosamine salt, 300g of vitamin K and 50g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 8
Weighing 200g of calcium carbonate, 150g of ossein, 300g of D-glucosamine salt, 200g of vitamin K and 30g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 9
Weighing 120g of calcium carbonate, 150g of ossein, 280g of D-glucosamine salt, 220g of vitamin K and 40g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 10
Weighing 230g of calcium carbonate, 160g of ossein, 270g of D-glucosamine salt, 260g of vitamin K and 44g of casein phosphopeptide, and uniformly mixing to obtain the target composition with the function of repairing articular cartilage.
Example 11
The preparation is taken to treat patients who are clinically recruited to meet the knee osteoarthritis, and the treatment effect of partial cases is as follows:
1) after the composition with the function of repairing articular cartilage, which is prepared in example 8, is taken by Liu women in the Hebei Shijiazhuang Luquan area for 33 years due to lumbar pain, symptoms are relieved, and the waist is bent and alive, so that the pain is low.
2) In the old male in the Queen flag camp district, the male is 52 years old, and due to the pain of the double knee joints, the difficulty of going up and down stairs and the difficulty of squatting, the composition with the function of repairing the articular cartilage, which is prepared in the example 3, can normally go up and down stairs and squat after being taken for 30 days, and the double knee joints are not painful.
3) When the composition with the function of repairing articular cartilage prepared in the example 5 is taken by plum women in Qingdao Shandong for knee joint pain, the pain is obviously relieved after the composition is taken for 7 days.
4) Wu-Ming women, 70 years old, have no obvious inducement to pain in the double knee joints 4 years ago, are persistent dull pain, have aggravated pain when going upstairs and downstairs for a long time, are relieved when having a rest, have difficulty going upstairs and downstairs, are accompanied by bone friction and weakness, have no morning stiffness and limited joint movement, have obviously relieved pain after taking the composition with the function of repairing articular cartilage prepared in the embodiment 9 for 3 months, and have much relaxation when going upstairs and downstairs.
5) Liu women in Kunming, age 51, have repeated pain in the right knee joint for more than 2 years and limited joint movement, and after taking the composition with the function of repairing articular cartilage prepared in example 2 for 2 months, the right knee joint has not developed pain for half a year.
6) Kunming Gunn women, aged 63 years, have no obvious inducement to pain before 10 years of the double knee joints, are continuously dull pain, are aggravated when walking, going up a slope and going up and down stairs, are relieved during rest, are accompanied by bone friction feeling, cannot squat, are accompanied by morning stiffness, and can relieve themselves after lasting for 5-6 minutes. After 3 months of administration of the composition having the function of repairing articular cartilage prepared in example 7, pain did not appear in the knee joints for half a year.
7) Kunming Zhongmai, aged 58 years old, had pain in the right knee joint before 50 years due to congenital dysplasia, was persistent dull pain, and the pain was aggravated when going up and down stairs, relieved when resting, difficulty of squatting, no bone friction sensation, morning stiffness, limited joint movement, and no special treatment was performed. After 3 months of administration of the composition having the function of repairing articular cartilage prepared in example 9, pain did not appear in the knee joints for half a year.
Test example 1
The composition having the function of repairing articular cartilage prepared in example 8 was tested, and the details were as follows:
the method comprises the following steps: the clinical curative effect of the preparation is analyzed according to related qualitative and quantitative indexes before and after taking the medicine by clinically collecting the patients who accord with the knee osteoarthritis to take the medicine.
1. Collecting cases: the collected cases were screened according to the diagnostic criteria for knee osteoarthritis.
2. The preparation is taken by 50 patients in the group 2 times a day, 2g each time, and each patient is treated for 1 treatment course (3 months).
3. Knee joint pain degree, osteoarthritis severity degree, bone metabolism correlation, serum inflammatory factor level and adverse reaction occurrence before and after treatment of patients in the group are compared. (1) The pain degree of the knee joint is evaluated by a Visual Analogue Scale (VAS), the score range is 0-10, and the higher the score is, the more serious the pain degree is; (2) the severity of knee osteoarthritis is evaluated by adopting The indexes of Western Ontario and McMaster Unveenws (WOMAC) and high-frequency ultrasound related data, The WOMAC is divided into 24 items, each item is divided into 0-10 points, and The higher The score is, The more serious The arthritis is; measuring the depth of effusion in the knee joint, the thickness of the synovial membrane in the suprapatellar bursa, the blood flow condition in the synovial membrane, the swelling degree of the meniscus on the inner side and the outer side, the thickness of the articular cartilage, the depth of the effusion, the thickening of the synovial membrane, the abundant blood flow in the synovial membrane, the obvious swelling of the meniscus and the thin articular cartilage which indicate the serious arthritis by high-frequency ultrasound (measurement before the beginning and at 6 weeks and 12 weeks after the administration); (3) bone metabolism is related to bone density of single-side femoral neck by adopting dual-energy X-ray bone density measurement, and serum calcium, phosphorus, alkaline phosphatase (ALP) and 25 hydroxyvitamin D (25 (OH) VitD) are measured by a full-automatic biochemical analyzer (measured before the beginning and at 12 weeks after administration); (4) serum inflammatory factor IL-1 beta and serum type II collagen C-telopeptide (CTX-II) were detected by flow cytometry (measurement before the start and at 12 weeks after administration). (5) Adverse reactions include nausea, vomiting, dizziness, lethargy, and the like.
4. As a result: from 1 week of treatment, the clinical symptoms of patients in the group are relieved, and the total effective rate of the gonarthritis is 87.3% and 93.4% in 6 weeks and 12 weeks. No adverse reactions were observed in 50 people.
Test example 2
The results of the tests conducted in examples 1, 2, 3, 4, 5, 6, 7, 9 and 10, respectively, and the same method as example 1 show that the composition having the function of repairing articular cartilage according to the present invention can alleviate clinical symptoms of patients and is effective in treating osteoarthritis of knee joint.
Claims (10)
1. The composition with the function of repairing the articular cartilage is characterized by comprising 100-300 parts by weight of calcium carbonate, 100-200 parts by weight of ossein, 200-400 parts by weight of D-glucosamine salt, 100-300 parts by weight of vitamin K and/or chondroitin sulfate and 10-50 parts by weight of casein phosphopeptide.
2. The composition with the function of repairing articular cartilage according to claim 1, which is characterized by comprising 150-265 parts by weight of calcium carbonate, 100-140 parts by weight of collagen, 200-400 parts by weight of D-glucosamine salt, 150-200 parts by weight of vitamin K and/or chondroitin sulfate and 10-30 parts by weight of casein phosphopeptide.
3. The composition for repairing articular cartilage according to claim 1, wherein the composition for repairing articular cartilage comprises calcium carbonate 200 parts, collagen 150 parts, D-glucosamine salt 300 parts, vitamin K and/or chondroitin sulfate 200 parts, and casein phosphopeptide 20 parts.
4. The composition for repairing articular cartilage according to claim 1, wherein the composition comprises 100 to 300 parts by weight of calcium carbonate, 100 to 200 parts by weight of collagen, 200 to 400 parts by weight of D-glucosamine salt, 100 to 300 parts by weight of vitamin K, and 10 to 50 parts by weight of casein phosphopeptide.
5. The composition with the function of repairing articular cartilage according to claim 4, which is characterized by comprising 150 to 265 parts by weight of calcium carbonate, 100 to 140 parts by weight of collagen, 200 to 400 parts by weight of D-glucosamine salt, 150 to 200 parts by weight of vitamin K and 10 to 30 parts by weight of casein phosphopeptide.
6. The composition for repairing articular cartilage according to claim 4, wherein the composition for repairing articular cartilage comprises the following raw materials, by weight, 200 parts of calcium carbonate, 150 parts of collagen, 300 parts of D-glucosamine salt, 200 parts of vitamin K, and 20 parts of casein phosphopeptide.
7. The composition with the function of repairing articular cartilage according to any one of claims 1-6, characterized in that said D-glucosamine salt is D-glucosamine hydrochloride or D-glucosamine potassium sulfate.
8. A preparation of the composition with the function of repairing articular cartilage according to any one of claims 1 to 6, which is characterized in that the composition with the function of repairing articular cartilage is added with pharmaceutically acceptable auxiliary materials to prepare tablets, powder, granules, capsules or pills.
9. The preparation of the composition with the function of repairing articular cartilage according to claim 8, which is characterized in that the tablet of the composition with the function of repairing articular cartilage consists of 180-250 parts of starch, 180-15 parts of povidone K3010 and 3-10 parts of magnesium stearate by weight, and the preparation method comprises the steps of pretreatment, granulation, drying and tabletting, and specifically comprises the following steps:
A. pretreatment:
1) uniformly mixing calcium carbonate, ossein, casein phosphopeptide, vitamin K and/or chondroitin sulfate and starch in a formula ratio, adding D-glucosamine salt, and uniformly mixing to obtain a material a;
2) dissolving povidone K30 in the formula ratio by using an ethanol solution with the volume percentage concentration of 30-80% to prepare a povidone K30 ethanol solution with the mass percentage concentration of 2-10% to obtain a material b;
B. preparing a soft material: mixing the material a and the material b, and granulating to obtain wet granules c;
C. and (3) drying: drying the wet particles c at the temperature of 50-70 ℃ to obtain dry particles d;
D. tabletting: tabletting the dry granules d to obtain a composition tablet with the target object having the function of repairing articular cartilage; coating to obtain the composition coated tablet with the function of repairing articular cartilage.
10. The application of the composition with the function of repairing articular cartilage according to any one of claims 1 to 4, which is characterized in that the composition with the function of repairing articular cartilage is applied to the preparation of medicines, foods and health-care foods for repairing degenerative joint diseases.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111643761.5A CN114191543A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
| CN202111521287.9A CN114010771A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111521287.9A CN114010771A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111643761.5A Division CN114191543A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114010771A true CN114010771A (en) | 2022-02-08 |
Family
ID=80068502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111643761.5A Pending CN114191543A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
| CN202111521287.9A Pending CN114010771A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111643761.5A Pending CN114191543A (en) | 2021-12-14 | 2021-12-14 | Composition with articular cartilage repairing function and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114191543A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178933A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Preparation for preventing and treating osteoporosis and osteoarthrosis |
| CN102318794A (en) * | 2011-10-19 | 2012-01-18 | 郭景龙 | Health-care food having calcium supplementing function |
| CN105412569A (en) * | 2015-12-24 | 2016-03-23 | 福和寿（武汉）健康管理有限公司 | Composition for increasing bone mineral density and preparation and preparation method thereof |
| CN105963317A (en) * | 2016-05-05 | 2016-09-28 | 南京素德问医药科技有限公司 | Pharmaceutical composition having function of improving bone density |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN104543674A (en) * | 2015-01-04 | 2015-04-29 | 北京世纪合辉医药科技股份有限公司 | Health food for improving bone and joint health as well as preparation method thereof |
-
2021
- 2021-12-14 CN CN202111643761.5A patent/CN114191543A/en active Pending
- 2021-12-14 CN CN202111521287.9A patent/CN114010771A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178933A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Preparation for preventing and treating osteoporosis and osteoarthrosis |
| CN102318794A (en) * | 2011-10-19 | 2012-01-18 | 郭景龙 | Health-care food having calcium supplementing function |
| CN105412569A (en) * | 2015-12-24 | 2016-03-23 | 福和寿（武汉）健康管理有限公司 | Composition for increasing bone mineral density and preparation and preparation method thereof |
| CN105963317A (en) * | 2016-05-05 | 2016-09-28 | 南京素德问医药科技有限公司 | Pharmaceutical composition having function of improving bone density |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114191543A (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN102178933B (en) | Preparation for preventing and treating osteoporosis and osteoarthrosis | |
| CN102318835B (en) | Composition for reducing bone loss and preparation method thereof | |
| CN1903220B (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| CN102894372A (en) | Health-care food for increasing bone density and preparation method thereof | |
| CN104188999A (en) | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN106072651B (en) | It is a kind of with increasing bone density, composition of anti-inflammatory and analgesic effect and preparation method thereof | |
| CN108720000B (en) | A kind of colostrum mineral salt calcium-supplementing preparation and preparation method thereof | |
| CN107348522A (en) | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof | |
| CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
| WO2013136871A1 (en) | Oversulfated chondroitin composition | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| CN103330197A (en) | Health-care food for improving osteoporosis | |
| CN114010771A (en) | Composition with articular cartilage repairing function and preparation and application thereof | |
| CN110522736A (en) | A kind of improvement sleep, the two-layer release-controlled tablet of beauty and preparation method | |
| CN103370062A (en) | Composition to increase joint and/or postural stability | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| AU2021101026A4 (en) | A nutritional composition for improving the motor system function of the elderly and its preparation method and application | |
| CN104721805A (en) | Granules for alleviating and preventing joint diseases and preparation method thereof | |
| CN110301647A (en) | The compound oligomeric peptide nutrient food of ground dragon protein | |
| KR102347731B1 (en) | Composition for activating zinc transporter | |
| CN113398241A (en) | Bone peptide composition, bone peptide tablet, preparation method and evaluation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |